Latanoprostene_bunod

Latanoprostene bunod

Latanoprostene bunod

Chemical compound

Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[3][4] It targets the trabecular meshwork directly.[4]

Quick Facts Clinical data, Trade names ...

References

  1. [1]
    "Search Page - Drug and Health Product Register". 23 October 2014.
  2. [2]
    "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Retrieved 7 June 2022.
  3. [3]
    "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension" (Press release). Valeant Pharmaceuticals International, Inc.
  4. [4]
    Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Latanoprostene_bunod, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.